Skip to main content
. 2020 Sep 1;137(10):1377–1391. doi: 10.1182/blood.2020007897

Figure 5.

Figure 5.

Leukemic blasts from pDC-AML upregulate a pDC transcriptional program. (A) Principal component analysis of gene expression in normal marrow CD34+ cells, normal pDCs, pDCs from pDC-AML, blasts from pDC-AML, blasts from AML without RUNX1 mutations or pDC expansion, and blasts from AML with RUNX1 mutations but no pDC expansion. (B) pDC transcriptional program, as evaluated by normalized single sample GSEA scores for each group. Scores are calculated based on expression levels of pDC genes. (C) Upset plot displaying overlap of upregulated genes among blasts from pDC-AML, blasts from AML without RUNX1 mutations or pDC expansion, and blasts from AML with RUNX1 mutations but no pDC expansion, pDCs from pDC-AML, and normal pDCs. All groups are compared with normal marrow CD34+ cells. (D) Heat map showing the 30 upregulated genes shared among blasts from pDC-AML, blasts from AML with RUNX1 mutations but no pDC expansion, and normal pDCs but not with blasts from AML without RUNX1 mutations or pDC expansion. (E) Gene ontology analysis showing upregulated pathways in blasts from pDC-AML compared with normal marrow CD34+ cells. (F) Expression levels of a subset of IFN-related genes upregulated in pDC-AML. These genes are also among the subset of genes depicted in panel D. **P < .01.